Antimutagenic Activity of Vitamins in Cultured Mammalian Cells

Kuroda, Yukiaki

doi:10.1007/978-1-4615-9561-8_20

Cited by 13 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results obtained in the present investigation with the lowest doses of VC are in agreement with the data of Kuroda [31], who showed the efficiency of simultaneous treatment with VC (100 mg/ml) as a desmutagen in reducing ethyl methanesulphonate-induced chromosomal damage in Chinese hamster V79 cells. Simultaneous treatment with VC also reduced the frequency of chromosomal aberrations induced by DMBA in cultured leukocytes [32].…”

Section: Contrary To In Vivo Studies In Vitro Investigations Have Insupporting

confidence: 92%

Protection and induction of chromosomal damage by vitamin C in human lymphocyte cultures

Antunes

Takahashi

1999

Teratog. Carcinog. Mutagen.

View full text Add to dashboard Cite

Some chemotherapeutic approaches have proposed the use of antioxidants such as vitamin C (VC) to minimize the cytotoxicity and damage induced in normal tissue by antitumor agents that produce free radicals. Nevertheless, VC can also be cytotoxic, genotoxic, and harmful when combined with antitumor agents in human cells in vitro. The present study was undertaken to investigate the effects of VC (100, 200, 500, and 1,000 μg/ml) on human peripheral blood lymphocytes in vitro and its anticlastogenic effect on chromosomal aberrations induced by doxorubicin (DXR). VC did not show a clastogenic effect by itself, except at 1,000 μg/ml. At the concentration of 100 or 200 μg/ml of VC, administered in pre‐, post‐, or simultaneous treatment, there was a significant reduction in both chromosome aberrations and number of abnormal metaphases induced by DXR. At the doses of 500 or 1,000 μg/ml, VC did not present the same protective effect and was cytotoxic. Under the present experimental conditions, the efficiency of VC in protecting against chromosome damage was dependent on the doses used. Teratogenesis Carcinog. Mutagen. 19:53–59, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

Section: Contrary To In Vivo Studies In Vitro Investigations Have Insupporting

confidence: 92%

Protection and induction of chromosomal damage by vitamin C in human lymphocyte cultures

Antunes

Takahashi

1999

Teratog. Carcinog. Mutagen.

View full text Add to dashboard Cite

show abstract

“…Ascorbate exhibits antimutagenic and anticarcinogenic effects in many situations [Shamberger, 1984[Shamberger, , 1985Kahl. 1986;Odagiri et al, 1988;Kogiso et al, 1988;Kuroda, 1988;Ghaskadbi and Vaidya, 19881. Epidemiological studies indicate a negative correlation between vitamin C consumption and risks for cancer at various sites Bartsch et al, 19881. In randomized trials in humans there are indications that supplementation with vitamins C and E decreases the incidence of some forms of cancer in susceptible populations [cf.…”

Section: Ascorbate (Ascorbic Acid Vitamin C) (Merck #846)mentioning

confidence: 99%

Antimutagens and anticarcinogens: A survey of putative interceptor molecules

Hartman¹,

Shankel²

1990

Environ and Mol Mutagen

248

View full text Add to dashboard Cite

In this review recent publications are cited for a number of antimutagens. The molecules surveyed are potential or proven "desmutagens" or "interceptors." These are biologically prevalent or synthetic molecules that are most often small metabolites proficient in binding to, or reacting with, mutagenic chemicals and free radicals. Many of this class of "blocking agents" are "soft" and "hard" nucleophiles with consequently varying abilities to react with particular classes of electrophiles, the major classes of direct-acting mutagens. Although they serve as a first line of defense against mutagens and carcinogens, many interceptor molecules are under-investigated with regard to their spectra of activity and their possible relevance to prophylaxis or treatment of human disease states.

show abstract